The activities of azlocillin, cefotaxime, and amikacin alone and in combination were evaluated in in vitro checkerboard studies, in infected neutropenic mice, and in human volunteers. The combination of cefotaxime plus amikacin was more synergistic in vitro than the others against the Enterobacteriaceae tested, and the combination of azlocillin plus amikacin was more synergistic against Pseudomonas aeruginosa and Staphylococcus aureus. Survival of neutropenic mice infected with Escherichia coli and Klebsiella pneumoniae, respectively, was greater with azlocillin plus amikacin (24 of 40 and 11 of 40) and with cefotaxime plus amikacin (21 of 40 and 17 of 40) than with azlocillin plus cefotaxime (22 of 40 and 3 of 40; P < 0.05). Median serum bactericidal activity in volunteers receiving these antibiotics alone and in combination was -1:8 with most agents and with all combinations tested against 10 strains each of E. coli, K. pneumoniae, P. aeruginosa, and S. aureus. These data suggest that clinical trials with combinations of azlocillin or cefotaxime plus amikacin deserve further study in febrile neutropenic patients.
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Overwhelming infections with gram-negative bacteria and Staphylococcus aureus occur frequently in granulocytopenic patients (7, 9, 24) . Early empiric combination antibiotic therapy is widely used in this clinical situation (7, 10, 18, 24) . Most therapeutic regimens include an aminoglycoside, such as gentamicin, tobramycin, or amikacin, and a broad-spectrum beta-lactam, such as carbenicillin or ticarcillin, or a cephalosporin. However, there is need for combinations with even broader activity and less toxicity than the above. The studies recorded in this report on the comparative activities of combinations of amikacin with azlocillin, a new broad-spectrum ureidopenicillin (29) , and cefotaxime, a new broad-spectrum cephalosporin (26) , were a response to that need. The studies were pursued collaboratively in three laboratories using (i) in vitro susceptibility testing, (ii) infected neutropenic mice, and (iii) serum from human volunteers who had received each drug alone and in combination. (21, 22) .
Animal studies. Animal studies were performed by using a modification of a neutropenic mouse model previously reported from this laboratory (6) . BALB/c mice (22 to 24 g) were made neutropenic with two intraperitoneal injections of 200 mg of cyclophosphamide per kg, separated by an interval of 54 to 56 h. This dosage schedule produced maximal granulocytopenia on day 4 after the first injection more consistently than did the single dose used in the earlier study. The leukocyte and granulocyte response to cyclophosphamide is shown in Fig. 1 .
On day 4 after the first cyclophosphamide injection, the mice were injected intraperitoneally with a bacterial inoculum in 0. Table 3 ) in an attempt to maximize the likelihood of showing an additive effect with the combinations.
Each antibiotic was injected subcutaneously in a volume of 0.2 ml 1 h after infection. A second treatment (same dose and volume) was injected 3 to 4 h later. Azlocillin, cefotaxime, and amikacin were given alone to groups of 20 to 40 infected mice and in combinations of two agents to other groups of 20 to 40) infected animals. The MIC of each antibiotic for each organism used, the 50% lethal dose, the infecting inoculum injected, and the doses of each drug are shown in Table 3 . Antibiotic levels were not measured in the mice. Results are reported as the number of survivors per treatment group, and the chi-square test for comparison of proportions was used in statistical analysis.
Studies in human volunteers. Three groups of six informed and consenting adult volunteers with normal renal and hepatic function received one infusion per day of a single dose of one antibiotic or a combination. Thus, one group of six received on 3 separate days azlocillin (75 mg/kg), amikacin, (7.5 mg/ kg), and the combination at the same doses. A second group of six received on 3 separate days one infusion of cefotaxime (15 mg/kg), amikacin (7.5 mg/kg), and the combination, and a third group of six received cefotaxime, azlocillin, and the combination of the two beta-lactam agents in the same doses as given above. Within each group, the order of administration was randomized by using a Latin square design so that, for example, two volunteers received azlocillin on dav 1, two received amikacin on day 1, and two received the combination as the first infusion.
Antibiotics were administered as intravenous infusions in 50 ml of 5% dextrose over 30 min. Sera were obtained at 1 and 6 h after infusion and were frozen at -20°C until used. Serum bactericidal activity of each of the 108 sera against each of 10 strains of E. coli, Klebsiella species, P. aeruginosa, and S. aureus was determined in microtiter plates with tryptic soy broth as the diluent (15) . These organisms were isolated from patients at the Institut Jules Bordet in Brussels. Gram-negative bacilli were studied at a final inoculum of 104 organisms per ml, and the staphylococci were studied at an inoculum of 10' organisms per ml. As described elsewhere (15) , the highest dilution of a given serum which resulted in a 99.9%( reduction of this inoculum represented the serum bactericidal activity.
RESULTS
In vitro studies. In vitro studies were done at the Wright-Fleming Institute, St. Mary's Hospital Medical School, London. Data regarding the susceptibility of the 197 strains tested to the three antibiotics are presented in Table 1 (4). MICs were lowest for cefotaxime against E. coli, Klebsiella species, P. mirabilis, and S. aureus. Amikacin was most active against Serratia species, and amikacin and azlocillin were most active against P. aeruginosa. Assays for beta-lactamase produced by these organisms were not performed. Table 2 . Of 108 Enterobacteriaceae tested, cefotaxime and amikacin were synergistic for 84 (78%) compared with 64 (59%) with azlocillin plus amikacin (P < 0.01) and 59 (50%) with azlocillin plus cefotaxime (P < 0.001). The combination of azlocillin plus amikacin was more frequently synergistic against P. aeruginosa and S. aureus than were the other combinations.
Animal experiments. Animal experiments were done at Roger Williams General Hospital, Providence, R.I. The inocula for the infecting doses and the doses used in the treatment of the infected neutropenic mice are presented in Table  3 . The results of therapy with the study antibiotics alone and in combination are presented in Table 4 . Subeffective doses approximating the PD2> of each antibiotic alone and in combination were used in these experiments. In practice, due to small variations in actual inoculum received and in recovery from neutropenia, all animals treated with low doses of single antibiotics or with saline did not always die.
In animals infected with E. coli, each combination of subeffective doses was significantly more effective than was each drug alone. In animals infected with K. pneumoniae, azlocillin plus amikacin was more effective than azlocillin alone, and cefotaxime plus amikacin was more active than either drug alone. In both of these groups of mice, azlocillin plus amikacin and cefotaxime plus amikacin were more active than the double beta-lactam combination ( 'LDr,5, 50% lethal dose; CFU, colony-forming units.
Median peak serum bactericidal activity (SBA) was .1:16 against E. coli and Klebsiella species for all three combinations (Table 5) . Most of the peak serum activity against these organisms in the cefotaxime plus amikacin group was due to cefotaxime, which produced similar activity when given alone. Median peak SBAs against these two organisms with azlocillin plus amikacin were similar to those found with each agent alone. With azlocillin plus cefotaxime, median SBA was considerably higher than with either drug alone. At 6 h after infusion (not shown in Table 5 ), 97 to 100% of sera from volunteers infused with cefotaxime plus amikacin and azlocillin plus cefotaxime had bactericidal activity -1:8 compared with only 55 and 39%7 for azlocillin plus amikacin against E. coli and Klebsiella species, respectively (P < 0.001).
Against P. aeruginosa, azlocillin plus amikacin was slightly more active than the other two combinations. At 6 h after infusion, 80% of the sera from volunteers receiving azlocillin plus amikacin had SBA -1:8 compared with 47% for cefotaxime plus amikacin and 58c for azlocillin plus cefotaxime.
For S. aureus, median peak SBA with cefotaxime plus amikacin was higher than with the other two combinations, but much of this activity was attributable to amikacin. At 6 h after infusion, none of the regimens produced much antistaphylococcal activity.
DISCUSSION Although different organisms were tested in each of the three experimental studies included in this report, taken together, the data indicate that the activities of combinations of azlocillin plus amikacin, cefotaxime plus amikacin, and, to a lesser extent The first multihospital EORTC study (7) and other studies (9) showed that E. coli, Klebsiella species, P. aeruginosa, and S. aureus are likely pathogens in the febrile neutropenic patient.
Successful treatment of gram-negative bacillemia in neutropenic patients has been achieved with combinations of broad-spectrum penicillins plus an aminoglycoside, cephalosporins plus an aminoglycoside, cephalosporins plus penicillins, and other combinations (11, 13, 18, 27) . Klastersky and colleagues (14, 16) gram-negative bacillemia who received synergistic antibiotics. Overall, there is some evidence that combination therapy is superior to singledrug therapy in cancer patients (2, 11, 13-16, 18, 27) . Combined antibiotic activity can be investigated by various methods, and Moellering (19) has commented recently that the presence of synergism may differ with these different techniques. The demonstration of antibiotic synergism in experimental infections is less well standardized than in in vitro studies, and the results are more variable. Moreover, there are no universally accepted criteria for in vivo synergism. Nonetheless, antibiotic combinations have been shown to be more effective than single agents in experimental models of rabbit endocarditis due to S. aureus (23) and rabbit staphylococcal osteomyelitis (20) . Animal experiments have demonstrated synergism against P. aeruginosa with carbenicillin plus gentamicin in neutropenic rats (25) and in a rabbit endocarditis model, although very high doses of aminoglycoside alone can produce bactericidal activity in sera greater than that found with the combination (3). Winston et al. (28) have demonstrated in neutropenic rats that cefazolin plus amikacin compared with amikacin alone produced greater rates of bacterial clearance and higher levels of SBA against strains of Klebsiella pneumoniae which were affected synergistically in vitro.
In the present study (Table 4) , deliberately suboptimal doses of azlocillin, cefotaxime, and amikacin were used alone and in combination to treat infections with gram-negative bacilli in neutropenic mice. Despite the many confounding variables mentioned above, combinationtherapy with azlocillin plus amikacin and cefotaxime plus amikacin were associated with significantly greater survival than was either drug alone at the same low doses used in the combination. The results were not as good with azlocillin plus cefotaxime. Obviously, this does not prove the presence of in vivo synergism rather (19) , it is of interest that the results obtained agree as well as they do. The in vitro checkerboard data showed more antagonism with the azlocillin plus cefotaxime combination than with the other combinations studied, especially against Klebsiella, Serratia, and Proteus species. Similarly, the neutropenic mouse model showed considerably less enhancement of survival in animals infected with E. coli and K. pneumoniae which were treated with this double beta-lactam combination than in infected animals treated with either beta-lactam in combination with amikacin. In the human volunteers, SBA was somewhat lower with azlocillin plus cefotaxime than with cefotaxime plus amikacin against S. aureus.
The potential for antagonism of beta-lactam agents in combination has been raised in several studies. Acar et al. (1) showed that the in vitro activity of carbenicillin or ampicillin against some strains of E. coli, Proteus species, and P. aeruginosa could be antagonized by cephaloridine, cloxacillin, or 6-amino-penicillanic acid. Graham 
